Elixir Names Praecis COO William Heiden President And CEO
This article was originally published in The Pink Sheet Daily
The ex-Schering-Plough exec most recently served as president and COO of Praecis. Elixir's previous CEO resigned to facilitate the firm's transition into a drug development company with a focus on near-term commercial opportunities.
You may also be interested in...
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles
Sepracor's television ads for its sleep aid Lunesta create brand recognition better than other new prescription drug direct-to-consumer ads, according to an analysis performed by IAG Research